1
Clinical Trials associated with siCoV/KK46An Open-safety Study of the siCoV/KK46 Drug Administered Via an Inhaled Route in Healthy Volunteers
This is an open-label, dose-escalation phase I study to assess the safety and tolerability of siCoV/KK46 in healthy volunteers. The purpose of this study is to determine the maximum daily dose of siCoV/KK46 as a single agent in adult healthy participants. Based on preclinical data from this institution, the investigators hypothesize that SARS-CoV-2 inhibition with siCoV/KK46 could potentially reduce pulmonary inflammation, thereby improving COVID-19 patient outcomes.
100 Clinical Results associated with siCoV/KK46
100 Translational Medicine associated with siCoV/KK46
100 Patents (Medical) associated with siCoV/KK46
100 Deals associated with siCoV/KK46